Patents Assigned to SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
  • Substituted pyrrolizines for the treatment of hepatitis B
    Patent number: 11591334
    Abstract: The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having a structure shown by the following formula (A1): or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof, that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 28, 2023
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Guoqin Fan, Cenbin Lu, Sai Yang, Xiaoguang Wang
  • JAK kinase inhibitor and preparation method and use thereof
    Patent number: 11524961
    Abstract: Provided is a selective JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, provided is a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 13, 2022
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Guoqin Fan, Sai Yang, Zhihong Zeng
  • Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
    Patent number: 11370766
    Abstract: Provided in the present application are a sulfonyl amidine as represented by formula (I) as an indoleamine-2,3-dioxygenase inhibitor, and a preparation method therefor and the use thereof. The compound of formula (I) in the present application can be used as an indoleamine-2,3-dioxygenase inhibitor in the preparation of a drug for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 28, 2022
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Zhihong Zeng
  • MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof and use thereof
    Patent number: 11299460
    Abstract: The present invention relates to an MDM2 inhabitor, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof specifically, the present invention relates to a compound represented by formula I. The compound has excellent MDM2 inhibitory activities, and can be used for preparing a pharmaceutical composition for treating cancers and other diseases related to MDM2 activities, particularly p53 wild-type cancer.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: April 12, 2022
    Assignee: Shanghai Longwood Biopharmaceuticals Co., Ltd.
    Inventors: Zhe Wang, Zhihong Zeng, Rongzhen Jiang
  • Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis B
    Patent number: 11168055
    Abstract: Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In particular, disclosed is a compound that can be used as an HBV replication inhibitor and has the structure as shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 9, 2021
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Xiaoguang Wang, Sai Yang, Zhihong Zeng